Drug metabolism data: Past and present status

Medicinal Chemistry Research

Volumn 8, Issue 7-8, 1998, Pages 400-421

  Erhardt, Paul W ^a  

^a UNIVERSITY OF TOLEDO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; NEW DRUG;

COMPUTER SYSTEM; CONFERENCE PAPER; DATA BASE; DEALKYLATION; DRUG DESIGN; DRUG HYDROLYSIS; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSFORMATION; HUMAN; NONHUMAN;

EID: 0032435330     PISSN: 10542523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (150)

1. Originally stated by the late Calvin Mooers during a panel discussion at the annual meeting of the American Documentation Institute at Lehigh University, Oct. 24, 1959, portions of which have been recently published in the Bulletin of the American Society for Information Science, 23, 22-23 (1996).
2. National Academy of Sciences (U.S.) Committee, Problems Of Drug Safety, Workshops, (1966-1968).
3. E. Boyland and J. Booth, The Metabolic Fate And Excretion Of Drugs, Ann. Rev. Pharmacol, 2, 129-142 (1962).
4. R. T. Williams, Detoxication Mechanisms In Man, Clin. Pharm. Ther., 4, 234-254 (1963).
5. J. R. Gillette, Metabolism Of Drugs And Other Foreign Compounds By Enzymatic Mechanisms, Prog. in Drug Res., 6, 11-73 (1963).
6. R. T. Williams, Detoxication Mechanisms. The Metabolism and Detoxication of Drugs, Toxic Substances and Other Organic Compounds, John Wiley & Sons, N.Y. (1959).
7. T B. Binns, Absorption and Distribution of Drugs, Williams & Wilkins, Baltimore, Md. (1964).
8. B. N. LaDu, H. G. Mandel and E. L. Way, Fundamentals of Drug Metabolism and Drug Disposition, Williams & Wilkins, Baltimore, Md. (1972).
9. J. W. Bridges and L. F. Chasseaud, Prog. In Drug Metab., Vol. 1, Wiley & Sons, N.Y. (1976).
10. The Chemical Society/The Royal Society of Chemistry (London), Foreign Compound Metabolism In Mammals, Volumes 4-6, Specialist Periodical Reports (1977, '79 and '81).
11. D. R. Hawkins, Biotransformations: A Survey Of The Biotransformations Of Drugs And Chemicals In Animals, Vol. 1-8, The Royal Society of Chemistry (1989-1995).
12. R. V. Smith, P. W. Erhardt and S. W. Leslie, Microsomal O-Demethylation, N-Demethylation And Aromatic Hydroxylation In The Presence Of Bisulfite And Dithiothreitol, Res. Comm. Chem. Path. Pharmacol, 12, 181-184 (1975).
13. T. Higuchi and V. Stella, Pro-drugs as Novel Drug Delivery Systems, Am. Chem. Society, Washington, D.C (1975).
14. H. Bundgaard, Design of Prodrugs, Elsevier, N.Y. (1985).
15. V. J. Stella and K. J. Himmelstein, Prodrugs And Site-Specific Drug Delivery, J. Med. Chem., 23, 1275-1282 (1980).
16. H. M. Deutsch, J. A. Glinski, M. Hernandez, R. D. Haugwitz, V. L. Narayanan, M. Suffness and L. H. Zalkow, Synthesis Of Congeners And Prodrugs. 3. Water-Soluble Prodrugs Of Taxol With Potent Antitumor Activity, J. Med. Chem., 32, 788-792 (1989).
17. P. W. Erhardt, Esmolol, Chronicles of Drug Discovery, 3, 191-206 (1993).
18. N. Bodor, R. Woods, C. Raper, P. Kearney and J. Kaminski, Soft Drugs. 3. A New Class Of Anticholinergic Agents. J. Med. Chem., 23, 474-480 (1980).
19. D. E. Atkinson, Cellular Energy Metabolism And Its Regulation, Academic Press, New York (1977).
20. M. L. Spann, K. C. Chu, W. T. Wipke and G. Ouchi, Use Of Computerized Methods To Predict Metabolic Pathways And Metabolites, J. Environ. Pathol. Toxicol, 2, 123 (1978).
21. T. H. Varkony, D. H. Smith and C. Djerassi, Computer-Assisted Structure Manipulation: Studies In The Biosynthesis Of Natural Products, Tetrahedron, 34, 841-852 (1978).
22. G. I. Ouchi, Computer-Assisted Prediction Of Plausible Metabolites Of Xenobiotic Compounds, Univ. Micro. Int., Univ. CA, Santa Cruz, CA (1978).
23. L. Goldberg, Structure-Activity Correlation As A Predictive Tool In Toxicology, Hemisphere, NY (1983).
24. J. F. Tinker and H. Gelernter, Computer Simulation Of Metabolic Transformation, J. Comput. Chem., 7, 657-665 (1986).
25. M. L. Mavrovounitis and G. Stephanopoulous, Computer-Aided Synthesis Of BiochemicalPathways, Biotechnol. Bioeng, 36, 1119-1132 (1990).
26. S. Barcza, L. A. Kelly and C. D. Lenz, Computerized Retrieval Of Information On Biosynthesis And Metabolic Pathways, J. Chem. Inform. and Comp. Sci., 30, 243-251 (1990).
27. F. Darvas, Metabol Expert: An Expert System For Predicting The Metabolism Of Substances, In QSAR in Environmental Toxicology II., K. L. Kaiser, Ed. Reidel Co., Dordrecht, 71-81 (1987).
28. F. Darvas, Predicting Metabolic Pathways By Logic Programming, J. Mol. Graphics, 6, 80-86 (1988).
29. Commercially available from ComGenex, Inc.
30. G. Klopman, M. Dimayuga and J. Talafous, META. 1. A Program For The Evaluation Of Metabolic Transformation Of Chemicals, J. Chem. Inform. Comp., Sci, 34, 1320-1325 (1994).
31. J. Talafous, L. M. Sayre, J. J. Mieyal and G. Klopman, META. 2. A Dictionary Model Of Mammalian Xenobiotic Metabolism, J. Chem. Inform. Comp. Sci, 34, 1326-1333 (1994).
32. Commercially available from MULTICASE, Inc.
33. E. M. Gifford, M. A. Johnson and C.-c. Tsai, Using The Xenobiotic Metabolism Database To Rank Metabolic Reaction Occurrences, Molecular Connections: The MDL Newsletter for Communicating with Customers, 13, 12-13 (1994).
34. Metabolite database is available from MDL Information Systems, Inc. Metabolite has 28,000 biotransformations based on 5,200 parent compounds and 20,000 molecular entries.
35. R. T. Williams, Comparative Patterns Of Drug Metabolism, Fed. Proc., 26, 1029-1039 (1967).
36. J. N. Smith, The Comparative Metabolism Of Xenobiotics, Adv. Comp. Physiol. Biochem, 3, 173-232 (1968).
37. J. N. Smith, Comparative Biochemistry Of Detoxification. Comp. Biochem, Ed. M. Florkin and H. S. Mason, Academic Press, N.Y., 403-457 (1964).
38. Conjugation Reactions In Drug Metabolism Taylor Francis London G. (1990).
39. K. W. DiBiasio, In Vitro Testicular Xenobiotic Metabolism Of Model Substrates In Rats, Mice, Monkeys, And Humans, Univ. Micro. Int., Univ. CA, Davis, CA, (1989).
40. J. Baron, J. M. Voigt, T. B. Whitter, T. T. Kawabata, S. A. Knapp, F. P. Guengerich and W. B. Jakoby, Identification Of Infratissue Sites For Xenobiotic Activation And Detoxication, Adv. Exp. Med. Biol., 197, 119-44 (1986).
41. E. M. Gifford, Applications Of Molecular Similarity To Visualize Xenobiotic Metabolism Structure-Reactivity Relationships, Ph.D. Thesis. The University of Toledo (1996).
42. K. Bachmann, D. Pardoe and D. White, Scaling Basic Toxicokinetic Parameters From Rat To Man, Env. Health Persp., 104, 400-407 (1996).
43. J. Sarver, D. White, P. Erhardt and K. Bachmann, Estimating Xenobiotic Half-Lives In Humans From Rat Data: Influence Of Log P, Env. Health Perspectives, Accepted (1997).
44. S. Hayashi, J. Watanabe, and K. Kawajiri, Genetic Polymorphisms In The 5′-Flanking Region Change Transcriptional Regulation Of The Human Cytochrome P450IIE 1 Gene, J. Biochem (Tokyo), 110, 559-565 (1991).
45. H. Sugimura, N. H. Caporaso, G. L. Shaw, R. V. Modali, F. J. Gonzalez, R. N. Hoover, J. H. Resau, B. F. Trump, A. Weston, C. C. Harris, Human Debrisoquine Hydroxylase Gene Polymorphisms In Cancer Patients And Controls, Carcinogenesis, 11, 1527-1530 (1990).
46. S. Kato, M. Onda, N. Matsukura, A. Tokunaga, T. Tajiri, D. Y. Kim, H. Tsuruta, N. Matsuda, K. Yamashita and P. G. Shields, Cytochrome P4502E1 (CYP2E1) Genetic Polymorphism In A Case-Control Study Of Gastric Cancer and Liver Disease, Pharmacogenetics, 5, S141-S144 (1995).
47. K. Tominaga, Y. Koyama, M. Sasagawa, M. Hiroki, and M. Nagai, A Case-Control Study Of Stomach Cancer And Its Genesis In Relation To Alcohol Consumption, Smoking and Familial Cancer History, Jpn J. Cancer Res, 82, 974-979 (1991).
48. A. Burger, Medicinal Chemistry 3rd Ed., I and II, Wiley-Interscience, New York (1970).
49. C. Wilson, O. Gisvold and R. Doerge, Textbook of Organic Medicinal And Pharmaceutical Chemistry, 6th ed., J. B. Lippincott, Philadelphia (1971).
50. Indeed, a systematic SAR investigation within medicinal chemistry can sometimes appear to be mundane in its desire to be thorough, e.g. the methodical examination of methyl- to ethyl- to n-propyl- substitution within a selected natural product only occasionally producing a totally unexpected biological consequence.
51. C. Hansch, P. P. Maloney, T. Fujita and R. M. Muir, Nature, 194, 178 (1962).
52. C. Hansch and T. Fujita, J. Am. Chem. Soc., 86, 1616 (1964).
53. C. Daniel and F. S. Wood, Fitting Equations To Data, Wiley, N.Y. (1971).
54. As knowledge about biological mechanisms and their related endogenous molecules accrued, medicinal chemists began to design appropriate ligand molecules ab initio, as opposed to using biologically active natural products as templates
55. T. L. Blundell and L. N. Johnson, Protein Crystallography, Academic Press, N.Y. (1976).
56. J. W. Erickson and S. W. Fesik, Macromolecular X-Ray Crystallography And NMR As Tools For Structure-Based Drug Design, Ann. Rep. Med. Chem., 27, 271-289 (1992).
57. K. Wuthrich, NMR of Proteins and Nucleic Acids, Wiley, N.Y. (1986).
58. S. W. Fesik, NMR Studies Of Molecular Complexes As A Tool In Drug Design, J. Med. Chem., 34, 2937-2945 (1991).
59. T. J. Perun and C. L. Propst, Computer-Aided Drug Design. Methods And Applications, Marcel Dekker, N.Y. (1989).
60. L. B. Kier and L. H. Hall, Molecular Connectivity in Chemistry and Drug Research, Academic Press, N.Y. (1976).
61. W. J. Murray, L. B. Kier, and L. H. Hall, Molecular Connectivity. 6. Examination Of The Parabolic Relationship Between Molecular Connectivity And Biological Activity, J. Med. Chem., 19, 573-578 (1976).
62. C. Humblet and G. R. Marshall, Pharmacophore Identification And Receptor Mapping, Ann. Rep. Med. Chem., 15, 267-276 (1980).
63. C. Humblet and J. B. Dunbar, 3D Database Searching And Docking Strategies, Ann. Rep. Med. Chem., 28, 275-284 (1993).
64. D. Bawden, Distance Geometry And Conformational Calculations, Wiley, N.Y. (1981).
65. D. Bawden, Distance Geometry And Molecular Conformation, Wiley, N.Y. (1988).
66. C. Ramsden, Comprehensive Medicinal Chemistry: The Rational Design Mechanistic Study And Therapeutic Application of Chemical Compounds, Vol. 4. Pergamon Press, Oxford (1990).
67. J. M. Blaney and J. S. Dixon, Receptor Modeling By Distance Geometry, Ann. Rep. Med. Chem., 26, 281-285 (1991).
68. A. Cammarata and G. K. Menon, Pattern Recognition. Classification Of Therapeutic Agents According To Pharmacophores, J. Med. Chem., 19, 739-748 (1976).
69. G. T. Toussaint, The Relative Neighborhood Graph Of A Finite Planar Set, Pattern Recognition, 12, 261-268 (1980).
70. G. Bemis and M. Murcko, The Properties of Known Drugs. I. Molecular Frameworks. J. Med. Chem., 39, 2887-2893 (1996).
71. M. Nicklaus, N. Neamati, H. Hong, A. Mazumder, S. Sunder, J. Chen, G. Milne and Y. Pommier, HIV-1 Integrase Pharmacophore: Discovery of Inhibitors through Three-Dimensional Database Searching. J. Med. Chem., 40, 920-929 (1997).
72. H. Hong, N. Neamati, S. Wang, M. Nicklaus, A. Mazumder, H. Zhao, T. Burke, Jr., Y. Pommier and G. Milne, Discovery of HIV-1 Integrase Inhibitors by Pharmacophore Searching. J. Med. Chem., 40, 930-936 (1997).
73. N. Neamati, H. Hong, A. Mazumder, S. Wang, S. Sunder, M. Nicklaus, G. Milne, B. Proksa and Y. Pommier, Depsides and Depsidones as Inhibitors of HIV-1 Integrase: Discovery of Novel Inhibitors through 3D Database Searching. J. Med. Chem., 40, 942-951 (1997).
74. 2 Inhibitors. J. Med. Chem., 40 1136-1148 (1997).
75. H. Matter, Selecting Optimally Diverse Compounds from Structure Databases: A Validation Study of Two-Dimensional and Three-Dimensional Molecular Descriptors. J. Med. Chem., 40, 1219-1229 (1997).
76. G. Klopman and H. S. Rosenkranz, Toxicity Estimation By Chemical Substructure Analysis: The TOX II Program, Tox. Lett., 79 145-155 (1995).
77. S. C. Basak, S. Bertelsen and G. D. Grunwald, Use Of Graph Theoretic Parameters In Risk Assessment Of Chemicals, Tox. Lett., 79, 239-250 (1995).
78. S. C. Basak and G. D. Grunwald, Predicting Mutagenicity Of Chemicals Using Topological And Quantum Chemical Parameters: A Similarity Based Study, Chemosphere, 31, 2529-2546 (1995).
79. Readers interested in recent information pertaining to structure-toxicity relationships may also want to check either of the following non-profit organizations: School of Chemistry at the University of Leeds (http://Chem.leeds.AC.UK/Luk); or The European Center for Ecotoxicology and Toxicology of Chemicals (ECETOC).
80. D. W. Matula and R. R. Sokal, Properties Of Gabriel Graphs Relevant To Geographical Variation Research And The Clustering Of Points In The Plane. Geographical Analysis, 12, 205-222 (1980).
81. X. Avula, R. Kalman, A. Liapis, E. Rodin, Mathematical Modelling in Science and Technology, Pergamon Press, N.Y. (1983).
82. C. Raychaudhury, S. K. Ray, J. J. Ghosb, A. B. Roy and S. C. Basak, Discrimination of Isomeric Structures Using Information Theoretic Topological Indices, J. Comp. Chem., 5. 581-588 (1984).
83. M. A. Johnson, Relating Metrics, Lines And Variables Defined On Graphs To Problems In Medicinal Chemistry. Graph Theory and Its Applications to Algorithms and Computer Science, Y. Alavi Ed., John Wiley, N.Y., 457-469 (1985).
84. S. C. Basak, V. R. Magnuson, G. J. Niemi, and R. R. Regal, Determining Structural Similarity Of Chemicals Using Graph-Theoretic Indices, Discrete App. Math., 19, 17-44 (1988).
85. S C. Basak, G. J. Niemi, and G. D. Veith, Predicting Properties Of Molecules Using Graph Invariants, J Math. Chem., 7, 243-272 (1991).
86. E. Gifford, M. A. Johnson and C.,-c. Tsai, A Graph-Theoretic Approach To Modeling Metabolic Pathways, J. Comp. Aided Mol. Design, 5, 303-322 (1991).
87. M. A. Johnson, C.-c. Tsai, and V. Nicholson, Chemical Stereographs: An Extension Of Chemical Graphs For Representing Stereochemical And Conformational Structures, J of Mathematical Chem., 7, 3-38 (1991).
88. E. M. Gifford, M. A. Johnson, D. G. Kaiser, and C.-c. Tsai, Visualizing Relative Occurrences In Metabolic Transformations Of Xenobiotics Using Structure-Activity Maps, J. Chem. Inform. Comp. Sci, 32, 591-599 (1992).
89. M. A. Johnson, Structure-Activity Maps For Graphically Analyzing Data In Nondimensional Metric Spaces Arising In Drug Design, J. Biopharm. Stat., 3, 203-236 (1993).
90. S. C. Basak and G. D. Grunwald, A Comparative Study Of Graph Invariants, Total Surface Area And Volume In Predicting Boiling Points Of Alkanes, Math. Mod. Sci. Comp., 2, 735-740 (1993).
91. S. C. Basak and G. D. Grunwald, Use Of Topological Space And Property Space In Selecting Structural Analogs, Math. Mod. Sci. Comp., 4, 100 (1995).
92. L. P. Lefcovitch, A Nonparametric Method For Comparing Dissimilarity Matrices, A General Measure Of Biogeographical Distance And Their Application, The Am. Nat., 123, 484-499 (1984).
93. M. A. Johnson, A Review And Examination Of The Mathematical Spaces Underlying Molecular Similarity Analysis, J. Math. Chem., 3, 117-145 (1989).
94. M. S. Lajiness, Molecular Similarity-Based Methods For Selecting Compounds For Screening, In Computational Chemical Graph Theory, D. H. Rouvray ed., Nova Science, N.Y. (1989).
95. M. A. Johnson and G. M. Maggiora, Concepts and Applications of Molecular Similarity, Wiley N.Y. (1990).
96. M. A. Johnson, G. M. Maggiora, M. S. Lajiness, J. B. Moon, J. D. Petke and D. C. Rohrer, Molecular Similarity Analysis Applications In Drug Discovery, In Advanced Computer-Assisted Techniques in Drug Discovery, H. van de Waterbeemd, ed., VCH, Weinheim (1994).
97. S. C. Basak and G. D. Grunwald, Molecular Similarity And Estimation Of Molecular Properties, J. Chem. Inf. Comput. Sci., 35, 366-372 (1995).
98. S. C. Basak and G. D. Grunwald, Estimation Of Lipophilicity From Molecular Structural Similarity, New J. Chem., 19, 231-237 (1995).
99. L. E. Gaudette and B. B. Brodie, Relationship Between The Lipid Solubility Of Drugs And Their Oxidation By Liver Microsomes, Biochem. Pharm., 2, 89-96 (1959).
100. R. E. McMahon, Demethylation Studies - I. The Effect Of Chemical Structure And LipidSolubility, J. Med. Pharm. Chem., 4, 67-78 (1961).
101. R. E. McMahon and N. R. Easton, Demethylation Studies - II The In Vitro Demethylation Of Dialkylmethylamines, J. Med. Pharm. Chem., 4, 437-445 (1961).
102. C. Hansch, A. R. Steward and J. Iwasa, The Use Of Substituent Constants In The Correlation Of Demthylation Rates, J. Med. Chem., 8, 868-870 (1965).
103. P. Mazel and J. F. Henderson, On The Relationship Between Lipid Solubility And Microsomal Metabolism Of Drugs, Biochem. Pharm., 14, 92-94 (1965).
104. Y. C. Martin and C. Hansch, Influence Of Hydrophobic Character On The Relative Rate Of Oxidation Of Drugs By Rat Liver Microsomes, J. Med. Chem., 14, 777-779 (1971).
105. C. Hansch, Quantitative Relationships Between Lipophilic Character And Drug Metabolism, Drug Metab. Rev., 1, 1-14 (1972).
106. C. Hansch and A. Leo, Substituent Constants For Correlation Analysis In Chemistry And Biology, Wiley, N.Y. (1979).
107. G. Galliana, B. R. Nali, S. Tollari, M. Rocchetti and M. Salmona, The Rate Of N-Demethylation Of N,N-Dimethylanilines And N-Methylanilines By Rat Liver Microsomes Is Related To Their First Ionization Potential, Their Lipophilicity And To A Steric Bulk Factor, Xenobiotica, 16, 511-517 (1986).
108. S. C. Devito and R. S. Pearlman, Physicochemical And Structural Factors Influencing Cyanide Release From Nitriles, Med. Chem. Res., 1, 461-465 (1992).
109. This term is meant to encompass the key structural elements within an overall structure which are pertinent for a given metabolic occurrence. It has been coined by analogy to the term pharmacophore.
110. S. Borman, Combinatorial Chemistry, C & E News 43-62, (February 24, 1997).
111. Note that this closing section for the Monograph's Introduction has been kept short so as to not pre-empt the Monograph's later section on Future Directions.
112. M. A. Gallop, R. W. Barrett, W. J. Dower, S. Fodor and E. M. Gordon, Applications Of Combinatorial Technologies To Drug Discovery. 1. Background And Peptide Combinatorial Libraries, J. Med. Chem., 37, 1234-1251 (1994).
113. E. M. Gordon, R. W. Barrett, W. J. Dower, S. Fodor and M. A. Gallop, Applications Of Combinatorial Technologies To Drug Discovery. 2. Combinatorial Organic Synthesis, Library Screening Strategies, And Future Directions, J. Med. Chem., 37, 1385-1401 (1994).
114. K. S. Brown, Drug, Biotech Firms Beginning To Embrace Combinatorial Chemistry, The Chemist, (May 13, 1996).
115. A. M. Ferguson, D. E. Patterson, C. D. Garr and T. L. Underiner, Designing Chemical Libraries For Lead Discovery, A. M. Majalli and A. L. Harris, Lead Generation Using Combinatorial Chemistry In Drug Discovery; K. C. Appell, T. D. Chung, M. J. Ohlmeyer, N. H. Sigal, J. J. Baldwin and D. Chelsky, Biological Screening Of A Large Combinatorial Library Journal of Biomolecular Screening 1, (1996).
116. A. M. Ferguson, D. E. Patterson, C. D. Garr and T. L. Underiner, Designing Chemical Libraries For Lead Discovery, A. M. Majalli and A. L. Harris, Lead Generation Using Combinatorial Chemistry In Drug Discovery; K. C. Appell, T. D. Chung, M. J. Ohlmeyer, N. H. Sigal, J. J. Baldwin and D. Chelsky, Biological Screening Of A Large Combinatorial Library Journal of Biomolecular Screening 1, (1996).
117. A. M. Ferguson, D. E. Patterson, C. D. Garr and T. L. Underiner, Designing Chemical Libraries For Lead Discovery, A. M. Majalli and A. L. Harris, Lead Generation Using Combinatorial Chemistry In Drug Discovery; K. C. Appell, T. D. Chung, M. J. Ohlmeyer, N. H. Sigal, J. J. Baldwin and D. Chelsky, Biological Screening Of A Large Combinatorial Library Journal of Biomolecular Screening 1, (1996).
118. P. J. Hylands and L. J. Nisbet, The Search For Molecular Diversity (I): Natural Products, Ann. Rep. Med. Chem., 26, 259-269 (1991).
119. W. J. Dower and S. P. Fodor, The Search For Molecular Diversity (II): Recombinant And Synthetic Randomized Peptide Libraries, Ann. Rep. Med. Chem., 26, 271-280 (1991).
120. W. H. Moos, G. D. Green, and M. R. Pavia, Recent Advances In The Generation Of Molecular Diversity, Ann. Rep. Med. Chem., 28, 315-324 (1993).
121. M. C. Venuti, The Impact Of Biotechnology On Drug Discovery, Ann. Rep. Med. Chem., 25, 289-298 (1990).
122. J. R. Collins, D. L. Camper, and G. H. Loew, Valproic Acid Metabolism By Cytochrome P450: A Theoretical Study Of Stereoelectronic Modulators Of Product Distribution. J. Am. Chem. Soc., 113, 2736-2743 (1991).
123. cam, J. Am. Chem. Soc., 113, 3195-3196 (1991).
124. D. Harris and G. Loew, Mechanistic Origin Of The Correlation Between Spin State And Spectra Of Model Cytochrome P450 Ferric Heme Proteins, J. Am. Chem. Soc., 115, 5799-5802 (1993).
125. cam, J. Am. Chem. Soc., 117, 4185-4186 (1995).
126. J. R. Halpert, Structural Basis Of Selective Cytochrome P450 Inhibition, Annu. Rev. Pharmacol, Toxicol., 35, 29-53 (1995).
127. K. M. Straub, P. Rudewicz and C. Garvie, Metabolic Mapping Of Drugs: Rapid Screening Techniques For Xenobiotic Metabolites With M.S./M.S. Techniques, Xenobiotica, 17, 413-422 (1987).
128. J. Berman, K. Halm, K. Adkison and J. Shaffer, Simultaneous Pharmacokinetic Screening of a Mixture of Compounds in the Dog Using API LC/MS/MS Analysis for Increased Throughput. J. Med. Chem., 40, 827-829 (1997).
129. R. Smith and J. Rosazza, Microbial Models Of Mammalian Metabolism, J. Pharm. Sci., 64, 1737 (1975).
130. J. P. Rosazza, M. Kammer, L. Youel, R. V. Smith, P. Erhardt, D. H. Truong and S. W. Leslie, Microbial Models Of Mammalian Metabolism O-Demethylations Of Papaverine, Xenobiotica, 7, 133-143 (1977).
131. R. V. Smith and J. P. Rosazza, Microbial Transformations As A Means Of Preparing Mammalian Drug Metabolites, Microb. Transform Bioact. Compd., 2, 1-42 (1982).
132. Examples of very recent efforts in this area include P. Karp and M. Riley's development of encyclopedias of E. Coli and H. Influenza genes and metabolism (http://www.ai.sri.com/ecocycl/ecocyc.html and /hircyc.html, respectively).
133. Also in this regard, interested readers may want to consider the somewhat analogous metabolic surveys that are being conducted in plant tissues, e.g. i) R. O. Mumma and R. H. Hamilton, Xenobiotic Metabolism In Higher Plants: In Vitro Tissue And Cell Culture Techniques, ACS Symp Ser., 97, 35-76 (1979); ii) R. H. Shimabukuro and W. C. Walsh, Xenobiotic Metabolism In Plants: In Vitro Tissue, Organ, And Isolated Cell Techniques, ACS Symp. Ser., 97 3-34 (1979), along with iii) The AGRO-version of Metabol Expert which is also available from ARSoftware Corp.
134. Also in this regard, interested readers may want to consider the somewhat analogous metabolic surveys that are being conducted in plant tissues, e.g. i) R. O. Mumma and R. H. Hamilton, Xenobiotic Metabolism In Higher Plants: In Vitro Tissue And Cell Culture Techniques, ACS Symp Ser., 97, 35-76 (1979); ii) R. H. Shimabukuro and W. C. Walsh, Xenobiotic Metabolism In Plants: In Vitro Tissue, Organ, And Isolated Cell Techniques, ACS Symp. Ser., 97 3-34 (1979), along with iii) The AGRO-version of Metabol Expert which is also available from ARSoftware Corp.
135. Also in this regard, interested readers may want to consider the somewhat analogous metabolic surveys that are being conducted in plant tissues, e.g. i) R. O. Mumma and R. H. Hamilton, Xenobiotic Metabolism In Higher Plants: In Vitro Tissue And Cell Culture Techniques, ACS Symp Ser., 97, 35-76 (1979); ii) R. H. Shimabukuro and W. C. Walsh, Xenobiotic Metabolism In Plants: In Vitro Tissue, Organ, And Isolated Cell Techniques, ACS Symp. Ser., 97 3-34 (1979), along with iii) The AGRO-version of Metabol Expert which is also available from ARSoftware Corp.
136. J. C. Gautier, P. Urban, P. Beaune and D. Pompon, Engineered Yeast Cells As Model To Study Coupling Between Human Xenobiotic Metabolizing Enzymes. Simulation Of The Two First Steps Of Benzo(a)Pyrene Activation, Eur. J. Biochem, 211, 63-72 (1993).
137. D. F. Lewis, C. Ioannides and D. V. Parke, Molecular Modelling Of Cytochrome CYP1A1: A Putative Access Channel Explains Differences In Induction Potency Between The Isomers Benzo(a)pyrene and Benzo(e)pyrene, And 2- And 4- Acetylaminofluorene, Tox. Lett., 71, 235-243 (1994).
138. D. F. Lewis, B. G. Lake and D. V. Parke, Molecular Orbital-Generated QSARs In A Homologous Series Of Alkoxyresorufins And Studies Of Their Interactive Docking With P450s, Xenobiotica, 25, 1355-1369 (1995).
139. D. F. Lewis and B. G. Lake, Molecular Modelling Of CYP1A Subfamily Members Based On An Alignment With CYP102: Rationalization Of CYP1A Substrate Specificity In Terms Of Active Site Amino Acid Residues, Xenobiotica, 26, 723-753 (1996).
140. D. F. Lewis and B. G. Lake, Molecular Modelling Of Members Of The P4502a Subfamily: Application To Studies Of Enzyme Specificity, Xenobiotica, 25, 585-598, (1995).
141. D. F. Lewis, C. Ioannides and D. V. Parke, A Quantitative Structure-Activity Relationship Study On A Series Of 10 Para-Substituted Toluenes Binding To Cytochrome P4502B4 (CYP2B4), And Their Hydroxylation Rates, Biochem. Pharm., 50, 619-625 (1995).
142. T. Walle, Assays of CYP2C8- and CYP3A4-mediated Metabolism of Taxol In Vivo and In Vitro. Methods in Enzymology, 272, 145-151 (1996).
143. S. A. Islam, C. R. Wolf, M. S. Lennard and M. J. Sternberg, A Three-Dimensional Molecular Template For Substrates Of Human Cytochrome P450 Involved In Debrisoquine 4-Hydroxylation, Carcinogenesis, 12, 2211-2219 (1991).
144. L. Koymans, N. P. Vermeulen, S. A. van Acker, J. M. te Koppele, J. J. Heykants, K. Lavrijsen, W. Meuldermans and G. M. Done-Op den Kelder, A Predictive Model For Substrates Of Cytochrome P450-Debrisoquine (2D6), Chem. Res. Toxicol, 5, 211-219 (1992).
145. M. J. de Grout, G. J. Buloo, K. T. Hansen and N. P. Vermeulen, Computer Prediction And Experimental Validation Of Cytochrome P4502D6-Dependent Oxidation Of GBR 12909, Drug Metab. and Disp., 23, 667-669 (1995).
146. M. J. de Groot, N. P. Vermeulen, J. D. Kramer, F. A. van Acker and G. M. Donne-Op den Kelder, A Three-Dimensional Protein Model For Human Cytochrome P4502D6 Based On The Crystal Structures Of P450 101, P450 102, And P450 108, Chem. Res. Toxicol., 9, 1079-1091 (1996).
147. D. F. Lewis, P. J. Eddershaw, P. S. Goldfarb, and M. H. Tarbit, Molecular Modelling Of CYP3A4 From An Alignment With CYP102: Identification Of Key Interactions Between Putative Active Site Residues And CYP3A-Specific Chemicals, Xenobiotica, 26, 1067-1086 (1996).
148. B. Testa and J. Caldwell, Prodrugs Revisited: The "Ad Hoc" Approach as a Complement to Ligand Design. Med. Res. Rev., 16, 233-241 (1996).
149. D. Smith, B. Jones and D. Walker, Design of Drugs Involving the Concepts and Theories of Drug Metabolism and Pharmacokinetics. Med. Res. Rev., 16, 243-266 (1996).
150. As stated by E. Garfield in A Tribute To Calvin N. Mooers, A Pioneer Of Information Retrieval, The Scientist, page 9 (March 17, 1997).